Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients

Lupus

Volumn 16, Issue 4, 2007, Pages 273-278

  Sachet, J C ^a   Borba, E F ^a   Bonfa E ^a   Vinagre, C G C ^a   Silva, V M ^a   Maranhao R C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atherosclerosis; Chloroquine; Dyslipoproteinemia; Emulsions; Lipoproteins; Low density lipoprotein; Systemic lupus erythematosus

Indexed keywords

CHLOROQUINE; LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DYSLIPOPROTEINEMIA; FEMALE; HUMAN; PRIORITY JOURNAL; RADIOACTIVITY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIRHEUMATIC AGENTS; CHLOROQUINE; CHOLESTEROL, LDL; FAT EMULSIONS, INTRAVENOUS; FEMALE; HUMANS; KINETICS; LIPOPROTEINS, LDL; LUPUS ERYTHEMATOSUS, SYSTEMIC; RADIOACTIVE TRACERS; RECEPTORS, LDL;

EID: 34249041999     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/09612033070160040901     Document Type: Article

References (70)

1. Avina-Zubieta JA, Galindo-Rodriguez G, Newman S et al. Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis 1998; 57: 582-587.
2. Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol 1997; 36: 799-805.
3. Wallace DJ. Antimalarials - the 'real' advance in lupus. Lupus 2001; 10(6): 385-387.
4. Rothfield N. Efficacy of antimalarials in systemic lupus erythematosus. Am J Med 1988; 85: 53-56.
5. Rudnicki RD, Gresham GE, Rothfield NF. The efficacy of antimalarials in systemic lupus erythematosus. J Rheumatol 1975; 2: 323-330.
6. Meinao IM, Sato EI, Andrade LE et al. Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus 1996; 5: 237-241.
7. The Canadian Hydroxychloroquine Study Group: A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-154.
8. Tsakonas E, Joseph L, Esdaile JM et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 1998; 7: 80-85.
9. Wallace DJ, Metzger AL, Stecher VJ et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 322-326.
10. Petri M, Lakata C, Magder L et al. Effect of prednisone and hydroxychloroquine on coronary artery disease risck factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994; 96: 254-259.
11. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996; 5 Suppl 1: S16-S22.
12. Bruce IN. 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 2005; 44: 1492-1502.
13. Petri M, Perez-Gutthann S, Spence D et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513-519.
14. Bruce IN, Gladman DD, Urowitz MB. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2000; 26: 257-278.
15. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus. Am J Epidemiol 1997; 145: 408-415.
16. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999; 42: 338-346.
17. Ward MM. Outcomes of hospitalizations for myocardial infarctions and cerebrovascular accidents in patients with systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3170-3176.
18. Ilowite NT, Samuel P, Ginzler E et al. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 1988; 31: 859-863.
19. Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity and anticardiolipin antibodies. Lupus 1997; 6: 533-539.
20. Borba EF, Bonfa E, Vinagre CGC et al. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1033-1040.
21. de Carvalho JF, Borba EF, Viana VS et al. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis Rheum 2004; 50: 3610-3615.
22. Ettinger WH, Goldberg AP, Applebaum-Bowden D et al. Dyslipoproteinemia in systemic lupus erythematosus: effect of corticosteroids. Am J Med 1987; 83: 503-508.
23. Ettinger WH Jr, Hazzard WR. Elevated apolipoprotein-B levels in corticosteroid-treated patients with systemic lupus erythematosus. J Clin Endocrinol Metab 1988; 67: 425-128.
24. MacGregor AJ, Dhillon VB, Binder A et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 152-155.
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-2497.
26. Hodis HN, Quismorio FP, Wickham E et al. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993; 20: 661-665.
27. Kavanaugh A, Adams-Huet B, Jain R et al. Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol 1997; 3: 3-8.
28. Rahman P, Gladman DD, Urowitz MB et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999; 26: 325-330.
29. Tam LS, Li EK, Lam CW et al. Hydroxychloroquine has no significant effect on lipids and apolipoproteins in Chinese systemic lupus erythematosus patients with mild or inactive disease. Lupus 2000; 9: 413-416.
30. Tam LS, Gladman DD, Hallett D et al. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000; 27: 2142-2145.
31. Borba EF, Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001; 28: 780-785.
32. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
33. Maranhão RC, Cesar TB, Pedroso-Mariani SR et al. Metabolic behavior in rats of a nonprotein microemulsion resembling low density lipoprotein. Lipids 1993; 28: 691-696.
34. Maranhao RC, Roland IA, Toffoletto O et al. Plasma kinetic behavior in hyperlipidemic subjects of a lipidic microemulsion that binds to LDL receptors. Lipids 1997; 32: 627-632.
35. Hirata RDC, Hirata MH, Mesquita CH et al. Effects of apolipoprotein B-100 on the metabolism of a lipid microemulsion model in rats. Biochim Biophys Acta 1999; 1437: 53-62.
36. Pinto LB, Wajgarten M, Silva EL et al. Plasma kinetics of a cholesterol-rich emulsion in young, middle-aged and elderly subjects. Lipids 2001; 36: 1307-1311.
37. Santos RD, Chacra AP, Morikawa A et al. Plasma kinetics of free and esterified cholesterol in familial hypercholesterolemia: effects of simvastatin. Lipids 2005; 40: 737-743.
38. Santos RD, Hueb W, Oliveira AA et al. Plasma kinetics of a cholesterol-rich emulsion in subjects with or without coronary artery disease. J Lipid Res 2003; 44: 464-469.
39. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
40. Bombardier C, Gladman DD, Urowitz MB et al., and the committee on prognosis studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640.
41. Ginsburg GS, Small DM, Atkinson D. Microemulsion of phospholipids and cholesterol esters: protein-free models of low density lipoprotein. J Biol Chem 1982; 257: 8216-8227.
42. 137C transfer rates in marine organisms and dose in man. J Radioan Nucl Chem 1998; 232: 233-236.
43. Maranhão RC, Feres MC, Martins MT et al. Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease. Atherosclerosis 1996; 126: 15-25.
44. Siedel J, Hägele EO, Ziegenhorn J et al. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 29: 1075-1080.
45. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982; 28: 2077-2080.
46. Warnick GR, Cheung MC, Albers JJ. Comparison of current methods for high-density lipoprotein cholesterol quantification. Clin Chem 1979; 25: 596-604.
47. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
48. Brunzell JD, Albers JJ, Haas LB et al. Prevalence of serum lipid abnormalities in chronic hemodialysis. Metabolism 1977; 26: 903-910.
49. Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia. Relation to renal function and dialysis. Nephron 1991; 57: 401-410.
50. Appel GB, Blum CB, Chien S et al. The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure and viscosity. N Engl J Med 1985; 312: 1544-1548.
51. Thompson GR, Soutar AK, Spengel FA et al. Defects of receptor-mediated low density lipoprotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism. Proc Soc Natl Acad Sci (USA) 1981; 78: 2591-2595.
52. Brown WV. Lipoprotein disorders in diabetes mellitus. Med Clin North Am 1994; 78: 143-161.
53. Heiss G, Tamir I, Davis CE et al. Lipoprotein-cholesterol distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation 1980; 61: 302-315.
54. Kannel WB, Hjortland MC, McNamara PM et al. Menopause and risk of cardiovascular disease. The Framingham Study. Ann Intern Med 1976; 85: 447-452.
55. Henkin Y, Como JA, Oberman A. Secondary dyslipidemia. Inadvertent effects of drugs in clinical practice. JAMA 1992; 267: 961-968.
56. Munro R, Morrison E, McDonald AG et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 374-377.
57. Innerarity TL, Mahley RW. Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry 1978; 17: 1440-1447.
58. Capell WH, Zambon A, Austin MA et al. Compositional differences of LDL particles in normal subjects with LDL subclass phenotype A and LDL subclass phenotype B. ArteriosclerThromb Vasc Biol 1996; 16: 1040-1046.
59. Ohmura H, Mokuno H, Sawano M et al. Lipid compositional differences of small, dense low-density lipoprotein particle influence its oxidative susceptibility: possible implication of increased risk of coronary artery disease in subjects with phenotype B. Metabolism 2002; 51: 1081-1087.
60. Chapman MJ, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J 1998; 19 Suppl A: A24-A30.
61. Maranhao RC, Garicochea B, Silva EL et al. Increased plasma removal of microemulsions resembling the lipid phase of low-density lipoproteins (LDL) in patients with acute myeloid leukemia. Braz J Med Biol Res 1992; 25: 1003-1007.
62. Maranhao RC, Garicochea B, Silva EL et al. Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia. Cancer Res 1994; 54: 4660-4666.
63. Middleton B, Middleton A. Cyclic AMP stimulates the synthesis and function of the low-density lipoprotein receptor in human vascular smooth-muscle cells and fibroblasts. Biochem J 1992; 282(3): 853-861.
64. Middleton A, Middleton B. Agents which increase cyclic AMP have diverse effects on low-density-lipoprotein-receptor function in human vascular smooth-muscle cells and skin fibroblasts. Biochem J 1990; 267(3): 607-614.
65. Powrie JK, Shojaee-Moradie F, Watts GF et al. Effects of chloroquine on the dyslipidemia of non-insulin-dependent diabetes mellitus. Metabolism 1993; 42: 415-419.
66. Gerstein HC, Thorpe KE, Taylor DW et al. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas - a randomized trial. Diabetes Res Clin Pract 2002; 55: 209-219.
67. Petri M, Spence D, Bone LR et al. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine 1992; 71: 291-302.
68. Bruce IN, Urowitz MB, Gladman DD et al. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999; 26: 2137-2143.
69. Svenungsson E, Jensen-Urstad K, Heimburger M et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001; 104: 1887-1893.
70. Abeles AM, Pillinger MH. Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? Arthritis Rheum 2006; 54: 393-407.